UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number: 001-42456
INLIF LIMITED
No. 88, Hongsi Road
Yangxi New Area, Honglai Town
Nan’an City, Quanzhou
The People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
On October 19, 2026, INLIF LIMITED, an
exempted company incorporated under the laws of the Cayman Islands (the “Company”), entered into a securities purchase
agreement (the “Securities Purchase Agreement”) with certain investors (the “Investors”) for a best-efforts
offering (the “Offering”) of an aggregate of (i) 435,000 Class A ordinary shares, par value of $0.0001 per share, of the
Company (each, a “Class A Ordinary Share”); (ii) pre-funded warrants to purchase up to 1,908,750 Class A Ordinary Shares
(each, a “Pre-Funded Warrant”); (iii) Series A warrants to initially purchase up to 2,343,750 Class A Ordinary Shares
(each, a “Series A Warrant”); (iv) Series B warrants to initially purchase up to 2,343,750 units (each, a “Series
B Unit”), each Series B Unit consisting of one Class A Ordinary Share, or one Pre-Funded Warrant in lieu thereof, and one
Series A Warrant (each, a “Series B Warrant”); and (v) Series C warrants, initially exercisable for zero Class A
Ordinary Shares, to purchase additional Class A Ordinary Shares up to 5,009,193 Class A Ordinary Shares (as defined below) (each, a
“Series C Warrant”). The offering price is $1.60 for one Class A Ordinary Share accompanied by one Series A Warrant, one
Series B Warrant and one Series C Warrant, or $1.5999 for one Pre-Funded Warrant accompanied by one Series A Warrant, one Series B
Warrant and one Series C Warrant. The Offering has total gross proceeds of $3.75 million, before deducting placement agent fees and
other offering expenses.
Each Pre-Funded Warrant represents the right to
purchase one Class A Ordinary Share at a remaining exercise price of $0.0001 per share, subject to adjustment. The Pre-Funded Warrants
are exercisable immediately and expire when exercised in full. Exercise is subject to a beneficial ownership limitation of 4.99% (or,
at the election of the holder, 9.99%), as provided in the applicable warrant. As of the date of this Report, all of the Pre-Funded Warrants
have been exercised.
The Series A Warrants are exercisable
immediately upon issuance at an initial exercise price of $1.60 per Class A Ordinary Share and will expire five (5) years after
closing. The Series B Warrants are exercisable immediately upon issuance at an initial exercise price of $1.60 per Series B Unit and
will expire sixty (60) days after issuance. Each of the Series A Warrants and Series B Warrants is subject to a one-time downward
exercise price reset (the “Reset Mechanism”) on the twentieth (20th) trading day (the “Series A and B
Reset Date”) after closing, to the lowest VWAP (as defined below) over the five trading days ending on the Series A and B Reset Date, with a proportionate increase
in the number of shares issuable under each of the Series A Warrants and Series B Warrants. Such Reset Mechanism underlying each Series
A Warrant and Series B Warrant is subject to a floor price of $0.51. along with other adjustments therein. The Series C Warrants has an exercise price of $0.0001 per
Class A Ordinary Share and are initially exercisable for zero Class A Ordinary Shares. On the tenth (10th) trading day after
issuance (the “Series C Reset Date,” and such ten-trading-day period ending on the Series C Reset Date, the
“Series C Reset Period”), the number of Class A Ordinary Shares issuable upon exercise of the Series C Warrants will be
increased, if the average daily volume weighted average price per Class A Ordinary Share (“VWAP”) during the Series C
Reset Period (subject to a floor price of $0.51) is below the offering price of $1.60, to the number of additional Class A Ordinary
Shares the holder would have received had it purchased its securities in the Offering at such lower price. If a holder exercises its Series C Warrant during the Series C Reset Period but prior to the Series C Reset Date, the Series C Reset Price
and the number of Class A Ordinary Shares issuable will be determined, solely with respect to the portion being exercised, as if the Series
C Reset Period had ended on the trading day immediately prior to the date of such exercise. The exercise price and
the number of shares issuable under each of the Series A Warrants, Series B Warrants and Series C Warrants will be proportionately
adjusted in the event of certain transactions involving our Class A Ordinary Shares, including stock dividends or share splits,
certain distributions and dividends, and rights offerings.
Notwithstanding the foregoing, if at any time
while the Series A Warrants and Series B Warrants are outstanding, there occurs any share split, share dividend, reverse share split,
or share combination, recapitalization or other similar transaction involving the Class A Ordinary Shares (each, a “Share Combination
Event”, and the date of such Share Combination Event (or if the Share Combination Event occurs after the close of trading on the
Nasdaq Capital Market, the trading day following such date), the “Share Combination Event Date”), then, in addition and after
giving effect to the adjustments for that Share Combination Event elsewhere in the Series A Warrants and Series B Warrants, the exercise
price shall be reduced, but in no event increased, to the lowest VWAP
during the period commencing five (5) consecutive trading days immediately preceding and ending on the fifth (5th) trading
day immediately following the Share Combination Event Date (as applicable, the “Event Market Price”); provided, that in calculating
the Event Market Price, the VWAP for trading days prior to the Share Combination Event Date shall be the VWAP reported after adjusting
for the Share Combination Event. The number of shares or units (as applicable) issuable under the Series A Warrants and Series B Warrants
will be increased such that the aggregate exercise price, after taking into account the decrease in the exercise price, shall be equal
to the aggregate exercise price on the issuance date for the warrant shares or units (as applicable) then outstanding (the “Share
Combination Event Adjustment”).
The Series A Warrants also contain certain downward
adjustment mechanism and anti-dilution provisions. If at any time while the Series A Warrants are outstanding, the Company sells, enters
into an agreement to sell, or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or
announce any offer, sale, grant or any option to purchase or other disposition) any Class A Ordinary Shares or securities convertible
or exercisable into Class A Ordinary Shares, except for certain exempt issuances (each a “Subsequent Equity Sale”) for a per
share price less than the then effective exercise price of the Series A Warrant in effect immediately prior to such Subsequent Equity
Sale (such lower price, the “Base Share Price”), the exercise price of the Series A Warrant shall be reduced to the lower
of (a) the Base Share Price and (b) the lowest VWAP during the period commencing five (5) consecutive trading days immediately preceding
and ending on the fifth (5th) trading day immediately following the public announcement of such dilutive issuance (as applicable,
the “New Issuance Price” and such period, the “New Issuance Adjustment Period”). Notwithstanding the foregoing,
if the Company enters into a variable rate transaction, the exercise price of the Series A Warrant shall be reduced to the lowest possible
price, conversion price or exercise price at which such securities may be issued, converted or exercised (the “Subsequent Equity
Sale Adjustment”).
Other than the Share Combination Event Adjustment
and Subsequent Equity Sale Adjustment stated above, in no event shall the exercise price of the Series A Warrants or Series B Warrants
be reduced below a floor price of $0.51, as adjusted for share dividends, share splits, stock combinations and other similar transactions.
The Securities Purchase Agreement contains customary
representations, warranties and covenants of the Company and the Investors, as well as customary indemnification obligations of the parties.
The Company issued Class A Ordinary Shares or Pre-Funded Warrants in lieu thereof accompanied by Series A Warrants, Series B Warrants
and Series C Warrants on October 20, 2026. The Company received gross proceeds, before deducting any fees or expenses, of approximately
$3.75 million. The Company intends to use the net proceeds from the Offering for the purchase of insurance coverage for the Company’s directors
and officers and for working capital purposes, including for the Phase II manufacturing facility, production and R&D equipment, its
Xiamen headquarters and R&D platform, new product R&D (including industrial robots), talent recruitment, and working capital,
with deployment expected over the next one to two years.
The Company’s securities described above
were offered pursuant to an effective registration statement on Form F-3 (SEC File No. 333-292580), that was previously filed with the
Securities and Exchange Commission (the “Commission”) on January 5, 2026, and declared effective on January 12, 2026 (the
“Registration Statement”), the base prospectus filed as part of the Registration Statement, and the prospectus supplement
dated October 19, 2026. The Registration Statement, the base prospectus and the prospectus supplement relating thereto are available on
the SEC’s website at www.sec.gov.
Placement Agency Agreement
The Company also entered into a placement agency
agreement dated October 19, 2026 (together, the “Placement Agency Agreement”), with Maxim Group LLC (the “Placement
Agent”), to act as the Company’s exclusive placement agent on a reasonable best-efforts basis in connection with the Offering.
The Company agreed to pay the Placement Agent a cash fee equal to 7% of the gross proceeds raised in the Offering, a cash fee equal to
7% of the gross proceeds provided to the Company upon the exercise of any Series B Warrants, and a reimbursement of expenses of up to
$50,000. In addition, the Company agreed to grant the Placement Agent the right of first refusal for a period of nine (9) months after
the closing of the Offering to act as the sole managing underwriter and book runner, or sole placement agent or sales agent, for any and
all future public or private equity, equity-linked or debt (excluding commercial bank debt) offerings for which the Company retains the
service of an underwriter, agent, advisor, finder or other person or entity in connection with such offering.
Lock-Up Restrictions
Pursuant to the Placement Agency Agreement and
the Securities Purchase Agreement, the Company has agreed to certain restrictions on the issuance and registration of any securities for
thirty (30) days following the closing of this Offering, subject to certain customary exceptions, without the prior written consent of
the Placement Agent.
In addition, the Company’s directors and
executive officers have entered into lock-up agreements (the “Lock-Up Agreements”) that generally prohibit the sale, transfer,
or other disposition of the Company’s securities for a period of ninety (90) days following the closing of the Offering, subject
to certain customary exceptions.
The foregoing description of the Placement Agency
Agreement, the Pre-Funded Warrants, the Series A Warrants, the Series B Warrants, the Series C Warrants, the Securities Purchase Agreement,
and the Lock-Up Agreements, are qualified in their entirety by reference to the full text of each of the Placement Agency Agreement, the
Pre-Funded Warrants, the Series A Warrants, the Series B Warrants, the Series C Warrants, the Securities Purchase Agreement, and the Lock-Up
Agreements, the forms of which are attached hereto as Exhibit 1.1, 4.1, 4.2, 4.3, 4.4, 10.1 and 10.2, respectively, to this Report, and
which are incorporated herein in their entirety by reference.
Copies of the opinions of Appleby and Ortoli Rosenstadt
LLP relating to the legality of the issuance and sale of the Class A Ordinary Shares, the Pre-Funded Warrants, the Series A Warrants,
the Series B Warrants, and the Series C Warrants, respectively, are filed as Exhibits 5.1 and 5.2 hereto, respectively.
Pursuant to the Offering, on October 19, 2026,
the Company issued a press release announcing the pricing of the Offering. A copy of the press release announcing the pricing of the Offering
is furnished as Exhibit 99.1 hereto. On October 20, 2026, the Company issued a press release announcing the closing of the Offering. A
copy of the press release announcing the closing of the Offering is furnished as Exhibit 99.2 hereto.
This Report, including the exhibits included hereto,
shall be incorporated by reference into: (i) the Company’s shelf registration statement on Form
F-3, as amended (File No. 333-292580) (the “Registration Statement”), which Registration Statement was declared
effective by the SEC on January 12, 2026, and (ii) the Company’s registration statement on Form
S-8 (File No. 333-289640), which was filed with the SEC on August 15, 2025, and into each prospectus or prospectus supplement outstanding
under the Registration Statement, to the extent not superseded by documents or reports subsequently filed or furnished by the Company
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
This Report shall not constitute an offer to sell
or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Forward-Looking Statements
This Report contains forward-looking statements.
Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations,
strategies, predictions or any other statements related to its future activities, future events or conditions. These statements are based
on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management.
These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due
to numerous factors, including those risks discussed in the Registration Statement, the Company’s most recent Annual Report on Form
20-F, and in other documents the Company files from time to time with the Commission. Any forward-looking statements speak only as of
the date on which they are made, and the Company undertakes no obligation to update any forward-looking statement to reflect events or
circumstances after the date of this Report, except as required by law.
Exhibit Index
| Exhibit No. |
|
Description |
| 1.1 |
|
Form of Placement Agency Agreement |
| 4.1 |
|
Form of Pre-Funded Warrant |
| 4.2 |
|
Form of Series A Warrant |
| 4.3 |
|
Form of Series B Warrant |
| 4.4 |
|
Form of Series C Warrant |
| 5.1 |
|
Opinion of Appleby |
| 5.2 |
|
Opinion of Ortoli Rosenstadt LLP |
| 10.1 |
|
Form of Securities Purchase Agreement |
| 10.2 |
|
Form of Lock-Up Agreement |
| 99.1 |
|
Press Release dated October 19, 2026 |
| 99.2 |
|
Press Release dated October 20, 2026 |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: October 21, 2026
| |
INLIF LIMITED |
| |
|
|
| |
By: |
/s/ Rongjun Xu |
| |
Name: |
Rongjun Xu |
| |
Title: |
Chief Executive Officer |
Exhibit 99.1
INLIF LIMITED Announces Pricing of $3.75 Million Registered Direct
Offering
Quanzhou, China, Oct. 19, 2026 (GLOBE NEWSWIRE) -- INLIF LIMITED (Nasdaq: INLF) (together with all its subsidiaries and consolidated entities,
the “Company” or “INLIF”), a company engaged in the research, development, manufacturing, and sales of injection molding
machine-dedicated manipulator arms, today announced that it has entered into securities purchase agreements with certain institutional
investors for the purchase and sale of an aggregate of 435,000 Class A Ordinary Shares, par value of US$0.0001 per share, of the Company
(the “Ordinary Shares”), pre-funded warrants to purchase up to 1,908,750 Ordinary Shares (the “Pre-Funded Warrants”),
Series A warrants to initially purchase up to 2,343,750 Ordinary Shares (the “Series A Warrants”), Series B warrants to initially
purchase up to 2,343,750 units (the “Series B Warrants”, each unit consisting of one Ordinary Share, or one Pre-Funded Warrant
in lieu thereof and one Series A Warrant ), and Series C warrants to purchase a number of Ordinary Shares to be determined in accordance
with their terms (the “Series C Warrants” and, together with the Series A Warrants and the Series B Warrants, the “Ordinary
Warrants”), in a registered direct offering (the “Offering”). Each Ordinary Share or Pre-Funded Warrant will be sold
together with one accompanying Series A Warrant, one accompanying Series B Warrant and one accompanying Series C Warrant at a combined
purchase price of US$1.60 per Ordinary Share and accompanying Ordinary Warrants, or US$1.5999 per Pre-Funded Warrant and accompanying
Ordinary Warrants, which equals the combined purchase price per Ordinary Share and accompanying Ordinary Warrants minus US$0.0001, the
exercise price of each Pre-Funded Warrant. The aggregate gross proceeds from the Offering are expected to be approximately US$3.75 million,
prior to deducting placement agent fees, legal fees, administrative and other offering-related expenses.
The Series A Warrants will be immediately exercisable
at US$1.60 per Ordinary Share and expire five years after closing. The Series B Warrants will be immediately exercisable at US$1.60 per
unit and expire 60 days after issuance. Each of the Series A Warrants and Series B Warrants is subject to a one-time downward exercise
price reset on the twentieth trading day after closing along with other adjustments therein. The Series C Warrants will be exercisable
at US$0.0001 per share for additional Ordinary Shares determined by a price-based adjustment over the first ten trading days beginning
on issuance.
The transaction is expected to close on or about
October 20, 2026, subject to the satisfaction of customary closing conditions.
Maxim Group LLC is acting as the sole placement
agent for the offering. Ortoli Rosenstadt LLP is acting as U.S. securities counsel to the Company, and Pryor Cashman LLP is acting as
U.S. securities counsel to the placement agent, in connection with the Offering.
The registered direct offering is being made pursuant
to the Company’s registration statement on Form F-3 (File No. 333-292580) previously filed with the U.S. Securities and Exchange
Commission (“SEC”), which was declared effective by the SEC on January 12, 2026. A prospectus supplement relating to the securities
will be filed by the Company with the SEC. All information filed with the SEC can be obtained over the internet on the SEC’s website
located at http://www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when
available, from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745 or by email at syndicate@maximgrp.com.
This press release does not constitute an offer
to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About INLIF LIMITED
INLIF is a holding company and an exempted company
incorporated in the Cayman Islands with limited liability. Through its operating entity in the People’s Republic of China, Ewatt Robot
Equipment Co. Ltd., established in September 2016, INLIF is engaged in the research, development, manufacturing, and sales of injection
molding machine-dedicated manipulator arms. It is also a provider of installation services and warranty services for manipulator arms,
and accessories and raw materials for manipulator arms. The Company produces an extensive portfolio of injection molding machine-dedicated
manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms,
and large bullhead multi-axis manipulator arms, all developed by itself. It has also built experience in industrial automation solutions,
including in the new energy sector, as well as intelligent robotics in recent years. For more information, please visit the Company’s
website: https://ir.yiwate88.com/.
Forward-Looking Statements
This press release contains forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking
statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events
and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial
needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,”
“anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,”
“potential,” “continue,” “is/are likely to” or other similar expressions, and includes such statements
regarding timing of closing, satisfaction of closing conditions, and expected proceeds from the offering. The Company undertakes no obligation
to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as
may be required by law.
These forward-looking statements are subject to
substantial risks and uncertainties that may cause actual results, performance or achievements to differ materially from those expressed
or implied, including without limitation: the Company’s ability to complete the Offering in accordance with the expected timeline
and terms; satisfaction of closing conditions; the planned use and actual deployment of net proceeds; adverse changes in global market
conditions and capital market sentiment; risks relating to the Company’s business strategy adjustment and asset optimization;
the ability to maintain the Company’s Nasdaq listing status; changes in industry policies and regulatory rules; future capital financing
needs; and other risk factors disclosed in the Company’s periodic filings and subsequent submissions with the SEC, including its
Annual Report on Form 20-F.
Although the Company believes that the expectations
expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct,
and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the Company’s registration statement and in its other filings with the
U.S. Securities and Exchange Commission.
Contact
INLIF LIMITED
Investor Relations Department
Email: ir@yiwate88.com
Exhibit 99.2
INLIF LIMITED Announces Closing of US$3.75 Million Registered Direct
Offering
Quanzhou, China, Oct. 20, 2026 (GLOBE NEWSWIRE) -- INLIF LIMITED (Nasdaq:
INLF) (together with all its subsidiaries and consolidated entities, the “Company” or “INLIF”), a company engaged
in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms, today announced the closing
of its previously announced registered direct offering conducted on a best-efforts basis.
The Company issued an aggregate of 435,000 Class A Ordinary Shares,
par value of US$0.0001 per share, of the Company (the “Ordinary Shares”), pre-funded warrants to purchase up to 1,908,750
Ordinary Shares (the “Pre-Funded Warrants”), Series A warrants to initially purchase up to 2,343,750 Ordinary Shares (the
“Series A Warrants”), Series B warrants to initially purchase up to 2,343,750 units (the “Series B Warrants”,
each unit consisting of one Ordinary Share, or one Pre-Funded Warrant in lieu thereof and one Series A Warrant), and Series C warrants
to purchase a number of Ordinary Shares to be determined in accordance with their terms (the “Series C Warrants” and, together
with the Series A Warrants and the Series B Warrants, the “Ordinary Warrants”), in a registered direct offering (the “Offering”).
Each Ordinary Share or Pre-Funded Warrant was sold together with one accompanying Series A Warrant, one accompanying Series B Warrant
and one accompanying Series C Warrant at a combined purchase price of US$1.60 per Ordinary Share and accompanying Ordinary Warrants, or
US$1.5999 per Pre-Funded Warrant and accompanying Ordinary Warrants, which equals the combined purchase price per Ordinary Share and accompanying
Ordinary Warrants minus US$0.0001, the exercise price of each Pre-Funded Warrant.
The Series A Warrants are immediately exercisable at US$1.60 per Ordinary
Share and will expire five years after closing. The Series B Warrants are immediately exercisable at US$1.60 per unit and will expire
60 days after issuance. Each of the Series A Warrants and Series B Warrants is subject to a one-time downward exercise price reset on
the twentieth trading day after closing along with other adjustments therein. The Series C Warrants will be exercisable at US$0.0001 per
share for additional Ordinary Shares determined by a price-based adjustment over the first ten trading days beginning on issuance.
The Company received total gross proceeds of approximately US$3.75
million, prior to deducting placement agent fees, legal fees, administrative and other offering-related expenses. The Company intends
to use the net proceeds from the Offering for the Company’s directors and officers and for working capital purposes, including the
Phase II manufacturing facility, production and R&D equipment, its Xiamen headquarters and R&D platform, new product R&D (including
industrial robots), talent recruitment, and working capital, with deployment expected over the next one to two years.
Maxim Group LLC acted as the sole placement agent for the Offering.
Ortoli Rosenstadt LLP acted as U.S. securities counsel to the Company, and Pryor Cashman LLP acted as U.S. securities counsel to the placement
agent, in connection with the Offering.
The Offering was made pursuant to the Company’s “shelf”
registration statement on Form F-3 (File No. 333-292580), initially filed with the U.S. Securities and Exchange Commission (the “SEC”)
on January 5, 2026 and declared effective on January 12, 2026. A final prospectus supplement and accompanying prospectus describing the
terms of the Offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov.
This press release is for informational purposes only and does not
constitute an offer to sell or a solicitation of an offer to buy any securities. No offering, sale or solicitation shall be permitted
in any jurisdiction where such offering or sale would be unlawful prior to registration, exemption or qualification under the local securities
laws of such jurisdiction.
About INLIF LIMITED
INLIF is a holding company and an exempted company incorporated in
the Cayman Islands with limited liability. Through its operating entity in the People's Republic of China, Ewatt Robot Equipment Co. Ltd.,
established in September 2016, INLIF is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated
manipulator arms. It is also a provider of installation services and warranty services for manipulator arms, and accessories and raw materials
for manipulator arms. The Company produces an extensive portfolio of injection molding machine-dedicated manipulator arms, including transverse
single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator
arms, all developed by itself. It has also built experience in industrial automation solutions, including in the new energy sector, as
well as intelligent robotics in recent years. For more information, please visit the Company's website: https://ir.yiwate88.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements
involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial
trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors
can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,”
“anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,”
“potential,” “continue,” “is/are likely to” or other similar expressions, and includes such statements
regarding timing of closing, satisfaction of closing conditions, and expected proceeds from the offering. The Company undertakes no obligation
to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as
may be required by law.
These forward-looking statements are subject to substantial risks and
uncertainties that may cause actual results, performance or achievements to differ materially from those expressed or implied, including
without limitation: the Company’s ability to complete the Offering in accordance with the expected timeline and terms; satisfaction
of closing conditions; the planned use and actual deployment of net proceeds; adverse changes in global market conditions and capital
market sentiment; risks relating to the Company’s business strategy adjustment and asset optimization; the ability to maintain
the Company’s Nasdaq listing status; changes in industry policies and regulatory rules; future capital financing needs; and other
risk factors disclosed in the Company’s periodic filings and subsequent submissions with the SEC, including its Annual Report on
Form 20-F.
Although the Company believes that the expectations expressed in these
forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions
investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that
may affect its future results in the Company’s registration statement and in its other filings with the U.S. Securities and Exchange
Commission.
Contact
INLIF LIMITED
Investor Relations Department
Email: ir@yiwate88.com
